INTRODUCTION

- Acute kidney injury (AKI) is common with coronavirus disease 2019 (COVID-19) infections.
- The incidence of AKI is up to ~50%, and about 20% of patients with COVID-19 will require continuous renal replacement therapy (CRRT).
- A major limitation of CRRT is premature filter clotting.
- Studies show that COVID-19 patients are hypercoagulable and have increased filter clotting.
- The purpose of this study is to investigate filter lifespan and average dose delivered of CRRT in patients with COVID-19 in the medical intensive care unit at Vidant Medical Center.

MATERIALS & METHODS

- This is a single center retrospective cohort study.
- Manual electronic chart review will be performed to obtain patient demographics, comorbidities, dates of hospitalization, dates of death, dates of CRRT initiation, time on CRRT, and average lifespan of filters.
- We will also collect data on causes of filter clotting and average dose of CRRT delivered vs prescribed dose.

REFERENCES